Clinical trials: Atopic Dermatitis
Atopic Dermatitis
POC Study to Evaluate BSI-045B in Moderate-to-severe Atopic Dermatitis
The study is a multicenter clinical trial and is designed as a proof-of-concept study to evaluate the efficacy, safety, tolerability, PK, immunogenicity, and PD of BSI-045B following SC injections.
- Trial name
- ADAMANT (NCT05932654)
- Testing
- BSI-045B
- Where
- 17 sites in United States
- Volunteers
- 22 people
- Sponsor
- Biosion, Inc.
Atopic Dermatitis Eczema, Atopic Dermatitis
Team-Based Connected Health (TCH) to Improve Clinical Outcomes and Access in Atopic Dermatitis
This is a pragmatic, randomized, controlled, equivalency trial. This 12-month trial will evaluate the impact of an online, team-based connected health (TCH) model for management of atopic dermatitis (AD) as compared to in-person…
- Conditions
- Atopic Dermatitis Eczema, Atopic Dermatitis, Eczema
- Trial name
- TCH in AD (NCT03981926)
- Testing
- Team-Based Connected Health (TCH)
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- University of Southern California
Healthy, Atopic Dermatitis
A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis
The main purpose of this study is to evaluate the safety and tolerability of LY3872386 in healthy participants and participants with atopic dermatitis. The safety of prednisone is also evaluated in healthy participants.
- Trial name
- NCT06119529
- Testing
- LY3872386, Prednisone
- Where
- 2 sites in United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Dermatitis, Atopic
A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
The purpose of this non-interventional observational study is to learn about the safety and effects of the medicinal product (called Abrocitinib) for the potential treatment of moderate to severe atopic dermatitis (AD).
- Trial name
- NCT05250115
- Where
- 38 sites in Germany
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Pfizer
Atopic Dermatitis
Dupilumab Skin Barrier Function Study in Atopic Dermatitis
Primary Objective: Evaluate changes in skin barrier function with transepidermal water loss (TEWL) assessed after skin tape stripping (STS) in pre-defined lesional skin in participants with moderate to severe atopic dermatitis…
- Trial name
- BALISTAD (NCT04447417)
- Testing
- Dupilumab SAR231893
- Where
- 2 sites in United States, Canada
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Sanofi
Atopic Dermatitis
SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients"
Primary Objective: To evaluate the effect of dupilumab on sleep quality in adult participants with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT04033367
- Testing
- Dupilumab
- Where
- 42 sites in United States, Australia and 8 more
- Volunteers
- 188 people
- Sponsor
- Sanofi
Dermatitis Atopic
Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis
Primary Objective: Assess change in neuronal architecture following long term treatment with dupilumab in skin biopsies from atopic dermatitis (AD) participants with chronic pruritus.
- Trial name
- DIFFEREN-STAD (NCT04823130)
- Testing
- Dupilumab (SAR231893)
- Where
- 3 sites in United States, Germany
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Sanofi
Dermatitis Atopic
Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis
Primary Objective: Evaluate changes in skin barrier function with transepidermal water loss (TEWL) assessed after skin tape stripping (STS) in predefined lesional skin in pediatric participants with moderate to severe atopic…
- Trial name
- PELISTAD (NCT04718870)
- Testing
- Dupilumab SAR231893
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Sanofi
Atopic Dermatitis
Phase 2a Study of the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic Dermatitis
This was a Ph2a study that consists of a double-blind, intra-patient placebo-controlled treatment period and an open-label uncontrolled treatment period with objective to evaluate the safety, tolerability, PK and preliminary…
- Trial name
- NCT04992546
- Testing
- PRN473 (SAR444727)
- Where
- 12 sites in United States, Canada
- Volunteers
- 39 people
- Sponsor
- Principia Biopharma, a Sanofi Company
Atopic Dermatitis
Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis
This is an open-label, multicenter study to evaluate the systemic exposure and safety of topical tapinarof cream, 1% under conditions of maximal use in pediatric subjects with atopic dermatitis
- Trial name
- NCT05186805
- Testing
- Tapinarof cream, 1%
- Where
- 10 sites in United States, Canada
- Volunteers
- 36 people
- Sponsor
- Organon and Co
Atopic Dermatitis
Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults
This is a double-blind, randomized, vehicle controlled Phase 3 study to evaluate the efficacy and safety of topical tapinarof cream, 1% compared to vehicle control cream in pediatric and adult subjects with atopic dermatitis.
- Trial name
- NCT05014568
- Testing
- tapinarof cream, 1%, Vehicle cream
- Where
- 67 sites in United States, Canada
- Volunteers
- 407 people
- Sponsor
- Organon and Co
Atopic Dermatitis
Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102)
This is a double-blind, randomized, vehicle controlled Phase 3 study to evaluate the efficacy and safety of topical tapinarof cream, 1% compared to vehicle control cream in pediatric and adult subjects with atopic dermatitis.
- Trial name
- NCT05032859
- Testing
- tapinarof cream, 1%, vehicle cream
- Where
- 62 sites in United States, Canada
- Volunteers
- 406 people
- Sponsor
- Organon and Co
Dermatitis, Atopic
Clinical Effect, Safety and Tolerability of GSK1070806 in Atopic Dermatitis
This study will evaluate efficacy and safety of GSK1070806 in moderate to severe atopic dermatitis (AtD) participants.
- Trial name
- NCT04975438
- Testing
- GSK1070806
- Where
- 11 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- GlaxoSmithKline
Atopic Dermatitis
Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis
This Phase 2a trial will evaluate the effects of EP262 in subjects with atopic dermatitis
- Trial name
- EASE (NCT06144424)
- Testing
- Oral EP262
- Where
- 10 sites in United States, Canada
- Volunteers
- 32 people
- Sponsor
- Escient Pharmaceuticals, Inc
Dermatitis, Atopic, Dermatitis
Effect of Benralizumab in Atopic Dermatitis
Atopic Dermatitis (AD), also known as eczema, is a common skin disease characterized by itchy lesions. The prevalence of AD has increased over the past few decades, with 15-30% of children and 2-10%of adults being affected.
- Conditions
- Dermatitis, Atopic, Dermatitis, Eczema, Skin Diseases
- Trial name
- NCT03563066
- Testing
- Benralizumab
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- McMaster University
Atopic Dermatitis, Atopic Disorders
A Community-based Assessment of Skin Care, Allergies, and Eczema
Atopic dermatitis (AD) affects over 9 million children in the U.S. and often heralds the development of asthma, food allergy, skin infections and neurodevelopmental disorders.
- Conditions
- Atopic Dermatitis, Atopic Disorders, Eczema, Atopic Eczema
- Trial name
- CASCADE (NCT03409367)
- Testing
- Participant choice of over-the-counter emollients: Vaseline, Vanicream, CeraVe Healing Ointment, CeraVe cream, Cetaphil cream
- Where
- 4 sites in United States
- Volunteers
- 1,260 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Atopic Dermatitis
Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis
This is an open-label, long-term multicenter, study to evaluate the safety and efficacy of topical tapinarof cream, 1% in subjects with atopic dermatitis.
- Trial name
- NCT05142774
- Testing
- Tapinarof cream, 1%
- Where
- 112 sites in United States, Canada
- Volunteers
- 728 people
- Sponsor
- Organon and Co
Atopic Dermatitis
A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic…
- Trial name
- Flex-Up (NCT05507580)
- Testing
- Upadacitinib
- Where
- 106 sites in Australia, Belgium and 16 more
- Volunteers
- 461 people
- Sponsor
- AbbVie
Atopic Dermatitis
Lebrikizumab Pen Ease of Use in Participants With Atopic Dermatitis
The purpose of this study is to assess the ease of use of the lebrikizumab pen. Participants will use a practice pad to simulate administration of a dose.
- Trial name
- NCT06444165
- Testing
- Lebrikizumab Pen
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Eli Lilly and Company
Atopic Eczema/Dermatitis (Non-Specific)
Skin bioMARkers for Atopic Eczema Therapy Evaluation
The study aims to investigate two new non-invasive technologies for assessing skin properties to identify and validate a range of safety biomarkers that may be considered useful as primary outcome measures for evaluating the…
- Trial name
- SMART (NCT04194814)
- Testing
- crisaborole (2%) ointment, betamethasone valerate 0.1% cream
- Where
- United Kingdom
- Volunteers
- 37 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust